Clinical Trial

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Study acronym: MINDSET 2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2025-05-09; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT06976203
Lead Sponsor Bristol-Myers Squibb
Conditions Alzheimer's Disease
Enrollment 586 participants
Start Date 2025-07-21
Primary Completion 2028-09-11 (estimated)
Study Completion 2029-02-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-12